Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actavis launches Docetaxel single vial

Actavis launches Docetaxel single vial

30th November 2010

Actavis has launched the Docetaxel single vial cancer drug in a number of markets following the patent expiry.

The company has used its own brand to launch the drug in the UK, Sweden, Germany and the Netherlands, while it is also being launched by third-party sales division Medis in the UK and Germany.

Vice-president of Actavis Hospital Business Unit Jonathan Ody said: "Actavis is delighted to be able to bring to the market a high quality single vial formulation of Docetaxel, the largest oncology product ever to go off patent in Europe."

In support of the launch, the company is offering the drug in a new 140 mg vial size, alongside 20 mg and 80 mg offerings.

The product is the generic equivalent of the Sanovi Aventis drug Taxotere.

Earlier this month the company released another product upon patent expiry – Mycofenolatmofetil Actavis is the firm's generic equivalent of Roche's Cellcept, which is used to lower immunity after liver, kidney or heart transplant.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.